111 related articles for article (PubMed ID: 27932792)
21. Thalidomide versus placebo in myeloid metaplasia with myelofibrosis: a prospective, randomized, double-blind, multicenter study.
Abgrall JF; Guibaud I; Bastie JN; Flesch M; Rossi JF; Lacotte-Thierry L; Boyer F; Casassus P; Slama B; Berthou C; Rodon P; Leporrier M; Villemagne B; Himberlin C; Ghomari K; Larosa F; Rollot F; Dugay J; Allard C; Maigre M; Isnard F; Zerbib R; Cauvin JM;
Haematologica; 2006 Aug; 91(8):1027-32. PubMed ID: 16885042
[TBL] [Abstract][Full Text] [Related]
22. Hairy cell leukemia (HCL) with extensive myelofibrosis responds to thalidomide.
Strupp C; Fenk R; Kündgen A; Gattermann N; Haas R; Germing U
Leuk Res; 2005 Aug; 29(8):967-9. PubMed ID: 15978949
[TBL] [Abstract][Full Text] [Related]
23. [Acquired chronic erythroblastopaenia followed by myelofibrosis. Remission with immunosuppressive therapy (author's transl)].
Clément F
Nouv Presse Med; 1979 Nov; 8(46):3817-20. PubMed ID: 534248
[TBL] [Abstract][Full Text] [Related]
24. Spliceosome mutations are common in persons with myeloproliferative neoplasm-associated myelofibrosis with RBC-transfusion-dependence and correlate with response to pomalidomide.
Chowdhury O; O'Sullivan J; Barkas N; Wang G; Buck G; Hamblin A; Tefferi A; Al-Ali HK; Barosi G; Devos T; Gisslinger H; Jiang Q; Kiladjian JJ; Mesa R; Passamonti F; Ribrag V; Schiller G; Vannucchi AM; Zhou D; McMullin MF; Zhong J; Gale RP; Mead AJ;
Leukemia; 2021 Apr; 35(4):1197-1202. PubMed ID: 32770086
[No Abstract] [Full Text] [Related]
25. Thalidomide plus prednisone with or without danazol therapy in myelofibrosis: a retrospective analysis of incidence and durability of anemia response.
Luo X; Xu Z; Li B; Qin T; Zhang P; Zhang H; Fang L; Pan L; Hu N; Qu S; Zhang Y; Huang G; Peter Gale R; Xiao Z
Blood Cancer J; 2018 Jan; 8(1):9. PubMed ID: 29335406
[TBL] [Abstract][Full Text] [Related]
26. Myelofibrosis: thalidomide finds a new disease.
Silver RT
Mayo Clin Proc; 2004 Jul; 79(7):857-8. PubMed ID: 15244380
[No Abstract] [Full Text] [Related]
27. Current treatment of myelofibrosis.
Silver R
Clin Adv Hematol Oncol; 2005 Apr; 3(4):269-70. PubMed ID: 16166999
[No Abstract] [Full Text] [Related]
28. [Pomalidomide for multiple myeloma].
Dougé A; Lemal R; Chaleteix C
Bull Cancer; 2017 Sep; 104(9):707-713. PubMed ID: 28583668
[TBL] [Abstract][Full Text] [Related]
29. Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.
Offidani M; Corvatta L; Caraffa P; Leoni P; Pautasso C; Larocca A; Palumbo A
Expert Rev Anticancer Ther; 2014 May; 14(5):499-510. PubMed ID: 24738833
[TBL] [Abstract][Full Text] [Related]
30. Darbepoetin-alpha for the anaemia of myelofibrosis with myeloid metaplasia.
Cervantes F; Alvarez-Larrán A; Hernández-Boluda JC; Sureda A; Granell M; Vallansot R; Besses C; Montserrat E
Br J Haematol; 2006 Jul; 134(2):184-6. PubMed ID: 16740139
[TBL] [Abstract][Full Text] [Related]
31. Myelofibrosis in a patient with pachydermoperiostosis.
Bachmeyer C; Blum L; Cadranel JF; Delfraissy JF
Clin Exp Dermatol; 2005 Nov; 30(6):646-8. PubMed ID: 16197378
[TBL] [Abstract][Full Text] [Related]
32. Resolution of post-polycythaemic myelofibrosis with a combination of thalidomide and interferon.
Hebballi S; Akiki S; Bareford D
J Clin Pathol; 2012 Aug; 65(8):762-3. PubMed ID: 22412053
[No Abstract] [Full Text] [Related]
33. [Effect of progesterone in anemia of idiopathic myelofibrosis].
Quiroga Vergara ER; Quiroga Micheo E
Medicina (B Aires); 1982; 42(5):581-2. PubMed ID: 7169948
[No Abstract] [Full Text] [Related]
34. Pomalidomide (Pomalyst) for multiple myeloma.
Med Lett Drugs Ther; 2015 Apr; 57(1467):e66-7. PubMed ID: 25988965
[No Abstract] [Full Text] [Related]
35. An usual cause of elliptocytosis.
Broséus J; Roth-Guépin G; D'Aveni-Piney M; Perrot A; Lesesve JF; Perrin J
Ann Biol Clin (Paris); 2016 Dec; 74(6):704-707. PubMed ID: 27734802
[TBL] [Abstract][Full Text] [Related]
36. Primary autoimmune myelofibrosis in a 36-year-old patient presenting with isolated extreme anemia.
Santos FP; Konoplev SN; Lu H; Verstovsek S
Leuk Res; 2010 Jan; 34(1):e35-7. PubMed ID: 19748119
[TBL] [Abstract][Full Text] [Related]
37. Haematological and molecular responses in refractory anaemia with ring sideroblasts and thrombocytosis treated with lenalidomide.
Caers J; Hafraoui K; Keutgens A; Caberg JH; Lambert F; Tassin F; Beguin Y
Eur J Haematol; 2014 Feb; 92(2):179-80. PubMed ID: 24299333
[No Abstract] [Full Text] [Related]
38. Pomalidomide.
Engelhardt M; Wäsch R; Reinhardt H; Kleber M
Recent Results Cancer Res; 2014; 201():359-72. PubMed ID: 24756804
[TBL] [Abstract][Full Text] [Related]
39. Pomalidomide: when expectations are understated.
Di Raimondo F; Conticello C
Future Oncol; 2017 Feb; 13(5s):1-2. PubMed ID: 28116940
[No Abstract] [Full Text] [Related]
40. Combined treatment with thalidomide, corticosteroids, and erythropoietin in patients with idiopathic myelofibrosis.
Benetatos L; Chaidos A; Alymara V; Vassou A; Bourantas KL
Eur J Haematol; 2005 Mar; 74(3):273-4. PubMed ID: 15693801
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
